STK11 and cardiac hypertrophy: Moreover, a mouse cardiac hypertrophy model showed that NAD+ treatment can inhibit pro-hypertrophic pathway and activate anti-hypertrophic LKB1-AMPK pathway by Sirt3-dependent deacetylation of LKB1 (29).